Nov. 4, 2013
/PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic
for HIV/AIDS. The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects on long-term anti-retroviral therapy (ART), despite a median duration of HIV infection of 21 years and baseline CD4 T-cell counts prior to SB-728-T treatment of <500 cells/µl. The data were presented at a translational medicine meeting organized by
publications and entitled, "What Will it Take to Achieve an AIDS-Free World?" which is being held in
November 3-5, 2013
"These data are very promising and demonstrate the important link between SB-728-T treatment and immune reconstitution of central memory and total CD4 T cells and lower HIV DNA levels in subjects at 12 months," said
, Ph.D., Co-Director & Chief Scientific Officer, The Vaccine & Gene Therapy Institute of
(VGTI Florida), who presented the data and whose laboratory carried out the immunologic analyses.
ART successfully suppresses viral load in most subjects, but a significant proportion, so called immunologic non-responders (INR), do not restore normal CD4 counts above 500 cells/µl. HIV-infected subjects who were classified as INR, enrolled in Sangamo's ongoing SB-728-902 clinical trial (Cohorts 1-3), received a single infusion of SB-728-T which resulted in a durable increase in total CD4 T-cells associated with increases in ZFN-modified CD4 central memory T-cells, specifically memory and stem cell-like cells (TSCM) which provide a long-lasting source of CCR5-modified CD4 T-cells. Notably, despite the increase in total CD4 T-cells, a long-term decrease in the peripheral blood mononuclear cell (PBMC) HIV reservoir was observed, as measured by proviral DNA using a sensitive assay technique.